EU to rule on safety of Novartis's Gilenya MS pill

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

EU to rule on safety of Novartis's Gilenya MS pill

Postby MSUK » Wed Apr 18, 2012 4:21 am


Europe's drug regulator will likely allow Novartis AG's Gilenya to stay on the market without asking for much stricter safety warnings as it concludes a review of the multiple sclerosis pill initiated after reports of heart problems and the death of a patient who took the drug.

The regulator's decision could come as early as Thursday, said the London-based European Medicines Agency, the body responsible for licensing Gilenya in Europe a year ago.

The EMA launched the in-depth study in January to assess Gilenya's benefits and risks, and recommended doctors closely monitor the hearts of patients after they have been given the first dose of the drug.

The review was prompted by reports of heart problems in patients taking Gilenya, as well as the November death of a 59-year-old patient in the U.S. less than 24 hours after taking the first dose of the drug. The EMA had aimed to give an update on Gilenya's safety in March, but delayed its decision by about a month as it finalises its review... Read More - ... ageid/1309
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to Gilenya


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service